Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
The present study aimed to explore patient preferences for attributes of advanced hepatocellular carcinoma (HCC) treatments. A stated preference survey was completed by 150 patients with HCC living in Europe. Overall survival (OS) was the most important attribute, closely followed by risk of diarrhea and hypertension, and other adverse event (AE) risks. Patients were willing to trade OS to reduce AE risks. While less important than OS and AEs, patients also preferred shorter waiting times, and one-off administration of selective internal radiation therapy and oral tablets over intravenous infusions. Although patients placed the most value on extending OS, they were willing to forego OS to avoid risk of treatment-related AEs, to maintain their quality of life.
Date Issued
2021-07-27
Date Acceptance
2021-07-02
Citation
Future Oncology, 2021, 17 (32), pp.4275-4287
ISSN
1479-6694
Publisher
Future Science Group
Start Page
4275
End Page
4287
Journal / Book Title
Future Oncology
Volume
17
Issue
32
Copyright Statement
© 2021 The Author(s). This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit
http://creativecommons.org/licenses/by/4.0/
http://creativecommons.org/licenses/by/4.0/
License URL
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000677719400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
atezolizumab
bevacizumab
discrete choice experiment
hepatocellular carcinoma
lenvatinib
microspheres
patient preferences
selective internal radiation therapy
sorafenib
treatment
ATEZOLIZUMAB PLUS BEVACIZUMAB
DISCRETE-CHOICE EXPERIMENTS
SORAFENIB
HCC
Publication Status
Published online
Date Publish Online
2021-07-27